Hayk Davtyan1, Anahit Ghochikyan2, Irina Petrushina3, Armine Hovakimyan2, Arpine Davtyan2, David H Cribbs4, Michael G Agadjanyan5. 1. Department of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, CA, USA; Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA. 2. Department of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, CA, USA. 3. Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA. 4. Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA; Department of Neurology, University of California, Irvine, Irvine, CA, USA. 5. Department of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, CA, USA; Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA. Electronic address: magadjanyan@immed.org.
Abstract
BACKGROUND: As a prelude to clinical trials we have characterized B- and T-cell immune responses in macaques to AD vaccine candidates: AV-1955 and its slightly modified version, AV-1959 (with 3 additional promiscuous Th epitopes). METHODS: T- and B-cell epitope mapping was performed using the ELISPOT assay and competition ELISA, respectively. RESULTS: AV-1955 and AV-1959 did not stimulate potentially harmful autoreactive T cells, but instead activated a broad but individualized repertoire of Th cells specific to the MultiTEP platform in macaques. Although both vaccines induced robust anti-Aβ antibody responses without producing antibodies specific to Th epitopes of MultiTEP platforms, analyses of cellular immune responses in macaques demonstrated that the addition of Th epitopes in the case of AV-1959 created a more potent, superior vaccine. CONCLUSION: AV-1959 is a promising vaccine candidate capable of producing therapeutically potent anti-amyloid antibody in a broader population of vaccinated subjects with high MHC class II gene polymorphisms.
BACKGROUND: As a prelude to clinical trials we have characterized B- and T-cell immune responses in macaques to AD vaccine candidates: AV-1955 and its slightly modified version, AV-1959 (with 3 additional promiscuous Th epitopes). METHODS: T- and B-cell epitope mapping was performed using the ELISPOT assay and competition ELISA, respectively. RESULTS:AV-1955 and AV-1959 did not stimulate potentially harmful autoreactive T cells, but instead activated a broad but individualized repertoire of Th cells specific to the MultiTEP platform in macaques. Although both vaccines induced robust anti-Aβ antibody responses without producing antibodies specific to Th epitopes of MultiTEP platforms, analyses of cellular immune responses in macaques demonstrated that the addition of Th epitopes in the case of AV-1959 created a more potent, superior vaccine. CONCLUSION:AV-1959 is a promising vaccine candidate capable of producing therapeutically potent anti-amyloid antibody in a broader population of vaccinated subjects with high MHC class II gene polymorphisms.
Authors: R Lyle Patton; Walter M Kalback; Chera L Esh; Tyler A Kokjohn; Gregory D Van Vickle; Dean C Luehrs; Yu-Min Kuo; John Lopez; Daniel Brune; Isidro Ferrer; Eliezer Masliah; Amanda J Newel; Thomas G Beach; Eduardo M Castaño; Alex E Roher Journal: Am J Pathol Date: 2006-09 Impact factor: 4.307
Authors: Igor Klyubin; Dominic M Walsh; Cynthia A Lemere; William K Cullen; Ganesh M Shankar; Vicki Betts; Edward T Spooner; Liying Jiang; Roger Anwyl; Dennis J Selkoe; Michael J Rowan Journal: Nat Med Date: 2005-04-17 Impact factor: 53.440
Authors: Christoph Wiessner; Karl-Heinz Wiederhold; Alain C Tissot; Peter Frey; Simone Danner; Laura H Jacobson; Gary T Jennings; Rainer Lüönd; Rainer Ortmann; Julia Reichwald; Mauro Zurini; Anis Mir; Martin F Bachmann; Matthias Staufenbiel Journal: J Neurosci Date: 2011-06-22 Impact factor: 6.167
Authors: Bao-Xi Qu; Qun Xiang; Liping Li; Stephen Albert Johnston; Linda S Hynan; Roger N Rosenberg Journal: J Neurol Sci Date: 2007-06-15 Impact factor: 3.181
Authors: Nina Movsesyan; Anahit Ghochikyan; Mikayel Mkrtichyan; Irina Petrushina; Hayk Davtyan; Purevdorj B Olkhanud; Elizabeth Head; Arya Biragyn; David H Cribbs; Michael G Agadjanyan Journal: PLoS One Date: 2008-05-07 Impact factor: 3.240
Authors: Hayk Davtyan; Anahit Ghochikyan; Armine Hovakimyan; Arpine Davtyan; Richard Cadagan; Annette M Marleau; Randy A Albrecht; Adolfo García-Sastre; Michael G Agadjanyan Journal: J Neuroimmunol Date: 2014-10-16 Impact factor: 3.478
Authors: Hayk Davtyan; Karen Zagorski; Irina Petrushina; Konstantin Kazarian; Natalie R S Goldberg; Janet Petrosyan; Mathew Blurton-Jones; Eliezer Masliah; David H Cribbs; Michael G Agadjanyan; Anahit Ghochikyan Journal: Neurobiol Aging Date: 2017-08-10 Impact factor: 4.673
Authors: Hayk Davtyan; Wesley W Chen; Karen Zagorski; Joy Davis; Irina Petrushina; Konstantin Kazarian; David H Cribbs; Michael G Agadjanyan; Mathew Blurton-Jones; Anahit Ghochikyan Journal: Vaccine Date: 2017-03-18 Impact factor: 3.641
Authors: A Joly-Amado; H Davtyan; K Serraneau; P Jules; A Zitnyar; E Pressman; K Zagorski; T Antonyan; A Hovakimyan; H J Paek; M N Gordon; D H Cribbs; N Petrovsky; M G Agadjanyan; A Ghochikyan; D Morgan Journal: Neurobiol Dis Date: 2019-10-17 Impact factor: 5.996
Authors: Michael G Agadjanyan; Karen Zagorski; Irina Petrushina; Hayk Davtyan; Konstantin Kazarian; Maxim Antonenko; Joy Davis; Charles Bon; Mathew Blurton-Jones; David H Cribbs; Anahit Ghochikyan Journal: Mol Neurodegener Date: 2017-05-05 Impact factor: 14.195